MCRPC OR ADVANCED/METASTATIC SOLID TUMORS

Clinical trials for MCRPC OR ADVANCED/METASTATIC SOLID TUMORS explained in plain language.

Never miss a new study

Get alerted when new MCRPC OR ADVANCED/METASTATIC SOLID TUMORS trials appear

Sign up with your email to follow new studies for MCRPC OR ADVANCED/METASTATIC SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New Triple-Action antibody takes on Hard-to-Treat cancers

Disease control Not yet recruiting

This early-phase study tests a new drug called HLX3902 in about 48 adults with advanced prostate cancer or other solid tumors that have stopped responding to standard treatments. The drug is a special antibody designed to help the immune system attack cancer cells. The main goals…

Matched conditions: MCRPC OR ADVANCED/METASTATIC SOLID TUMORS

Phase: PHASE1 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control

Last updated May 15, 2026 11:57 UTC

MCRPC OR ADVANCED/METASTATIC SOLID TUMORS

Get alerted when new MCRPC OR ADVANCED/METASTATIC SOLID TUMORS trials appear

New Triple-Action antibody takes on Hard-to-Treat cancers